Delving into the Latest Updates on Urania Therapeutics SAS with Synapse

Overview

A review.Modern drug discovery is a highly complex and multi-disciplinary activity that began at the turn of the twentieth century, and structural biol. started to have an impact in the seventies.The first drug derived from a structure-based approach, the antihypertensive captopril, an angio-tensin-converting enzyme inhibitor, was approved in 1981, followed by dorzolamide, a carbonic anhydrase inhibitor used for the treatment of glaucoma, in 1995.Structural biol. has been fully integrated in the pharmaceutical industry drug discovery pipeline, and many companies use both high-throughput screening and fragment screening to identify starting points for their small-mol. R&D programs.Two important criteria for pursuing a drug target are its druggability and the possibility to design selective drugs that do not bind closely related proteins to avoid potential adverse effects.Cryo-electron microscopy will be a most useful complementary technique to answer biol. questions, mostly by addressing large and/or dynamic macromol. complexes and challenging targets such as membrane proteins.

100 Deals associated with Urania Therapeutics SAS

Login to view more data

100 Translational Medicine associated with Urania Therapeutics SAS

Login to view more data